Author:
Sekar Vanitha,Kestens Dries,Spinosa-Guzman Sabrina,De Pauw Martine,De Paepe Els,Vangeneugden Tony,Lefebvre Eric,Hoetelmans Richard M. W.
Subject
Pharmacology (medical),Pharmacology
Reference10 articles.
1. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates;Meyer;Antimicrob Agents Chemother,2005
2. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor;King;J Virol,2004
3. Katlama C Carvalho MTM Cooper D et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary efficacy analysis of POWER 1 (TMC114-C213) July 2427, 2005
4. Grinsztejn B Arasteh K Clotet B et al. TMC114/r is well tolerated in 3-class-experienced patients: week 24 primary safety analysis of POWER 1 (TMC114-C213) July 2427, 2005
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献